| Literature DB >> 35745879 |
Patricia Garcia Ferreira1, Vitor Francisco Ferreira1,2, Fernando de Carvalho da Silva3, Cyntia Silva Freitas4,5, Patricia Ribeiro Pereira4,5,6, Vania Margaret Flosi Paschoalin4,5,6.
Abstract
Chitosan displays a dual function, acting as both an active ingredient and/or carrier for pharmaceutical bioactive molecules and metal ions. Its hydroxyl- and amino-reactive groups and acetylation degree can be used to adjust this biopolymer's physicochemical and pharmacological properties in different forms, including scaffolds, nanoparticles, fibers, sponges, films, and hydrogels, among others. In terms of pharmacological purposes, chitosan association with different polymers and the immobilization or entrapment of bioactive agents are effective strategies to achieve desired biological responses. Chitosan biocompatibility, water entrapment within nanofibrils, antioxidant character, and antimicrobial and anti-inflammatory properties, whether enhanced by other active components or not, ensure skin moisturization, as well as protection against bacteria colonization and oxidative imbalance. Chitosan-based nanomaterials can maintain or reconstruct skin architecture through topical or systemic delivery of hydrophilic or hydrophobic pharmaceuticals at controlled rates to treat skin affections, such as acne, inflammatory manifestations, wounds, or even tumorigenesis, by coating chemotherapy drugs. Herein, chitosan obtention, physicochemical characteristics, chemical modifications, and interactions with bioactive agents are presented and discussed. Molecular mechanisms involved in chitosan skin protection and recovery are highlighted by overlapping the events orchestrated by the signaling molecules secreted by different cell types to reconstitute healthy skin tissue structures and components.Entities:
Keywords: anti-inflammatory; antiaging; antimicrobial; antitumorigenic; chitosan/nanochitosan scaffolds; composites; drug delivery; wound-healing properties
Year: 2022 PMID: 35745879 PMCID: PMC9228519 DOI: 10.3390/pharmaceutics14061307
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1Major naturally abundant polysaccharides. Although cellulose, amylose, and amylopectin are D-glucose polymers, chitin and its deacetylated derivative, chitosan, are made up of D-glucosamine.
Figure 2Panel (A): chitin and chitosan acetylation and deacetylation without alteration of the degree of polymerization. Chitin acetylation varies from 1–3 (DS = 1–3). Panel (B): chitosan structural modifications through amino group reactions with butanoyl or hepatanoyl (A), pyridine (B) or chitosan fibers crosslinking with glutaraldehyde (C).
Figure 3Chitosan radical scavenger activity demonstrated in an antioxidant assay using DPPH (2,2-diphenyl-1-picrylhydrazyl) as the electron acceptor.
Figure 4Resveratrol encapsulated in chitosan microspheres crosslinked with vanillin can be administered to modulate metabolic dysfunctions.
Figure 5Chitosan nanoparticles functionalized by long-chain pyridinium salts to increase antimicrobial effectiveness.
Figure 6Molecular effects of chitosan nanoparticles on E. coli growth inactivation. Chitosan seems to interact with phospholipids, particularly phosphatidylethanolamine (PE), the most abundant phospholipid in E. coli, triggering the impermeabilization or disassembly of its outer membrane. The impermebialization of bacteria membrane by the nano-chitosan films inhibit glucose and O2 uptake, causing bacteria death. After exposure to nano-chitosan particles, E. coli experiences a differential expression of proteins involved in protein biosynthesis machinery and amino acid and purine nucleotide supply, as already demonstrated [38] and shown in the yellow rectangle at the lower right corner. When E. coli is exposed to Ag-nano-chitosans, an increase in reactive oxygen species is observed, followed by consequent damage to cellular structures, including proteins and nucleic acids. Chitosan and Ag nanoparticles, as well as cellular structures, are not represented in their real scale. This figure was drawn using the infographic maker Mind the Graph, available at https://mindthegraph.com.
Figure 7Alginate/chitosan nanocomposites as drug carriers can load several pharmaceuticals, such as lovastatin, doxorubicin, and gentamicin.
Figure 8Chitosan and agarose scaffolds.
Studies on chitosan formulations for skin protection and cosmeceutical applications.
| Chitosan or Chitosan Composite | Type of Assay | Biological Effect | Experimental Conditions | Ref. |
|---|---|---|---|---|
| Chitin nanofibril-hyaluronan block copolymeric nanoparticles (CN-HA) | In vitro | Antiaging activity | Eye cream applied twice a day and serum: 2/3 drops twice a day, three times a week for 60 days | [ |
| Chitin nanofibers and nanocrystals | In vitro | Skin protective effects | Nine tested conditions using nanofibers and nanocrystals at 4, 12, and 24 h post-application | [ |
| Chitosan-alginate nanoparticles | In vitro | Antimicrobial and anti-inflammatory activity | 1%, 0.5%, 0.2%, and 0.1% of chitosan-alginate nanoparticle/4 h | [ |
| Chitosan nanoparticles | In vitro | Antimicrobial activity | 0.5 and 1 mg/mL chitosan derivatives/24 h | [ |
| Silver-nanoparticle-incorporated chitosan-based membranes | In vitro | Antibacterial efficacy and wound-healing ability | 12 mg and 60 mg silver nitrate/chitosan-based membranes for 7 and 28 days | [ |
| Chitosan nanoparticle-containing dexamethasone sodium phosphate | In vitro | Anti-inflammatory activity | 4.19, 10.65, and 43.06% of dexamethasone/5 mg chitosan nanoparticles for 35 days | [ |
| Phosphatidylcholine hyaluronic acid chitin–nanofibrils complex | In vivo (volunteer patients) | Antiaging activity | Single injection (1 mL solution with 10 µg/mL block-polymer) every 7 days for 10 weeks | [ |
| Chitin nanofibril-hyaluronan nanoparticles (CN-HA) | In vitro and in vivo studies (women) | Antioxidant and anti-inflammatory activities | 2 mg/mL CN-HA nanoparticles for 60 days | [ |
| Carvacrol and eugenol chitosan nanoparticles | In vitro | Antioxidant activity | 0.125 mg/mL to 1 mg/mL | [ |
| Chitosan nanoparticles | In vitro | Drug delivery applications | 30% | [ |
| Chitosan nanofibers | In vivo (mice) | Antileishmanial wound | 20 wt% nanofibers as wound dressings, daily for 30 days | [ |
| Chitin nanofibrils | In vivo (rat) | Wound healing | 2 g/L chitin nanofibril for 15 days | [ |
| Chitin nanofibril-hyaluronan block copolymeric nanoparticles (CN-HA) | In vitro | Antiaging activity | Eye cream: applied two times a day; serum: 2/3 drops two times a day, three times a week (60 days) | [ |
| Chitin nanofibers and nanocrystals | In vitro | Skin protective effects | Nine tested conditions using nanofibers and nanocrystals at 4, 12, and 24 h post-application | [ |
| Chitosan-alginate nanoparticles | In vitro | Antimicrobial and anti-inflammatory activities | 1%, 0.5%, 0.2%, and 0.1% of chitosan-alginate nanoparticles/4 h | [ |
| Chitosan nanoparticles | In vitro | Antimicrobial activity | 0.5 and 1 mg/mL chitosan derivatives/24 h | [ |
| PVA/Chitosan hydrogel dressing loaded with PHMB | 1: In vitro | 1: Growth inactivation of | 5% PVA/chitosan (1:1) + PHMD 8.12 µg/mg dry sample | [ |
| Chitosan dressing–loaded iturin-AgNPs (CS-AgNPs) | In vivo (mice) | Faster wound healing and reduced | Wounds covered with 0.02 g/mL CS and iturin-AgNPs 10 μg/mL | [ |
| 2 chitosan-dialdehyde cellulose (2CS-DC) composite foam sponge | In vivo (rabbit) | Reduced hemostasis time by 79.5% or 47.7% | Amputated tail covered with 2:1 CS-DAC 0.02 g | [ |
| Oligo-chitosan (O-C) scaffold | Ex vivo (blood of (vWD) patients) | Increased release of PDGF and TGF-β1 by 29.8% and 23%, respectively; platelet activation, adhesion, and aggregation promotion | O-C 75–95% DDA applied to the blood | [ |
| Chitosan/titanium dioxide (CS/TiO2) composite membrane | In vitro | Fibroblast proliferation; increased cytokine expression; | CS/TiO2 membrane incorporated with 025% TiO2 | [ |
| Chitosan-PVA soft membranes plasticized with glycerol | In vivo (rabbit) | Burn wound healing in second-degree burns; inhibition of | Chitosan 80%, PVA 20%, and glycerol 2% | [ |
| Chitosan mesh membrane wound dressing | Clinical trial (skin donor patients) | Faster wound healing with no scar formation on the 10th day | 1% chitosan mesh membrane covering the wound for two months | [ |
| Chitosan sheet wound dressing | Clinical trial (skin donor patients) | Faster wound healing on the 11th day | No posology informed; wounds treated with chitosan sheets for six months | [ |
| Heparin-chitosan membrane wound dressing | Clinical trial (skin donor patients) | Wound-healing acceleration on the 12th day | Heparin 7% in 1% chitosan membrane covering the wound with 15-day follow up | [ |
| Chitosan-capped silver nanoparticles | In vivo (rat) | Burn wound healing | Ch/AgNPs to 50 mg/wound of the 1% silver sulfadiazine for 28 days | [ |
| Silver chitosan nanocomposites | In vitro | Antifungal | Nanocomposites: 0.06 to 16 μg/mL | [ |
| Chitosan-gentamicin (CS-GS) film | In vitro | Antibacterial— | CS-GS films immersed in PBS for 1, 3, 5, and 7 days were covered with 0.5 mL Log-phase bacteria suspension for 24 h | [ |
| Chitosan/glycosaminoglycan scaffolds-Ag Nanoparticles | In vitro | Antimicrobial— | Scaffold portion with Ag 385 μg/mL added to bacteria suspension for 24 h; | [ |
| Silver nanoparticles/chitosan oligosaccharide/PVA nanofibers | In vivo (rat) | Wound healing | 5% nanofibers for 18 days | [ |
PVA—polyvinyl alcohol; PHMB—polyhexanide; Ch—chitosan; DDA—degree of deacetylation; vWD—Von Willebrand disease.
Figure 9Main mechanisms involved in skin repair. Injured tissue naturally recovers through four subsequent and overlapping events orchestrated by mediator molecules secreted by different cell types to reconstitute skin structures and healthy tissue components. Chitosan interferes in several events (highlighted in bold) by stimulating signaling molecules. This figure compiled the mechanisms already described and was drawn using the infographic maker Mind the Graph available at https://mindthegraph.com.